Tag: ADOCIA
ADOCIA: Information relating to the number of shares and voting rights as of August 31, 2022 – 09/14/2022 at 6:00 p.m.
ADOCIA: Information relating to the number of shares and voting rights as of August 31, 20226 p.m. CEST – In accordance with the provisions of Article L.233-8 II of the…
Adocia strengthened its cash flow in the first half, which gives it financial visibility until the first half of 2024
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? Sale ? What course objective? Our experts engage and…
ADOCIA: Information relating to the number of shares and voting rights as of July 31, 2022 – 08/25/2022 at 6:00 p.m.
6 p.m. CEST – In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés…
Adocia received significant revenues in the first half
By Olivier Cheilan Published on 08/24/2022 at 6:20 p.m. Photo credit © Adocia / Tournaire…
ADOCIA publishes its cash position and its turnover for the second quarter and reports on its activities – 08/24/2022 at 18:00
• Strengthening of the cash position to €23.9 million as of June 30, 2022 following the receipt of a milestone payment of $5 million from Tonghua Dongbao (THDB) received in…
Adocia: a net increase in turnover in the second quarter – 08/24/2022 at 18:41
(AOF) – Adocia, a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, recorded an increase in its turnover in the second…
ADOCIA announces the half-year results of the Adocia liquidity contract entered into with Kepler Capital Markets – 07/20/2022 at 6:00 p.m.
6:00 p.m. CEST – Under the liquidity contract entrusted to Kepler Capital Markets relating to the shares of ADOCIA, the following resources appeared in the liquidity account on June 30,…
Adocia: Adocia’s insulin-amylin combo helps type 1 diabetics lose weight, study finds
(BFM Bourse) – A clinical trial has shown that Adocia’s “M1Pram” compound, which combines amylin with insulin (two hormones lacking in type 1 diabetic patients, “innate” diabetes), led to weight…
Adocia announces that the phase 2 trial with M1Pram has achieved its primary objective
By Claude Leguilloux Published on 06/21/2022 at 6:31 p.m. Photo credit © Reuters …
ADOCIA announces that the phase 2 trial with M1Pram has achieved its primary objective of weight loss in overweight people with type 1 diabetes – 06/21/2022 at 18:00
• Demonstrated weight loss over 4 months compared to Humalog® (-2.13 kg) with progressive and continuous weight loss, still ongoing at the end of the study period • Both treatments…
ADOCIA: Information relating to the number of shares and voting rights as of May 31, 2022 – 06/14/2022 at 6:00 p.m.
6 p.m. CEST – In accordance with the provisions of Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés…
Adocia: the annual general meeting will be held on June 28 – 05/23/2022 at 07:56
(AOF) – Adocia announces that its annual general meeting (AGM) will be held on June 28 at 10 a.m., at the Hôtel de Talleyrand, in the offices of the firm…